Spravato is the market benchmark for ketamine therapy. The next chapter is operational: REMS-ready site monitoring, ECHO-grade real-world evidence, and adherence intelligence across the entire certified site network.
See how we'd partner on SpravatoA nasal-spray NMDA receptor antagonist and the first ketamine-derived therapy approved for treatment-resistant depression. Now approved as monotherapy for MDD and on track for blockbuster status, with infrastructure scaling faster than the industry expected.
Spravato proved the commercial model for a controlled, in-clinic psychiatric intervention. It defined the REMS framework, the certified-treatment-center model, and the payer pathway that every psychedelic and ketamine competitor is now trying to replicate or undercut.
The result: a $1.7B blockbuster on track for $2.3B in 2026, with treatment centers expanding from 2,800 to 7,000+ in 24 months. That growth creates a new measurement problem: protocol fidelity, adherence, and real-world outcomes are now distributed across thousands of independent sites.
The ECHO real-world study across 570+ European and Israeli patients showed Spravato's effect persisted through 6 months after treatment discontinuation. That's the kind of evidence that wins payer expansion fights and defends against generic ketamine encroachment. But ECHO is one cohort. The next decade of Spravato's commercial story needs continuous RWE at network scale.
And with bretisilocin, COMP360, and long-acting ketamines all advancing toward the same patient population, differentiation now lives in outcome data, not mechanism stories.
From the FDA monotherapy approval to ECHO's durability data to the blockbuster sales trajectory.
The certified-treatment-center model that made Spravato's launch successful now creates four measurement gaps that standard reporting tools cannot close.
Spravato's REMS requires 2-hour post-dose observation, vital sign checks, and specific dosing intervals. Across 7,000 sites with varying staffing models, fidelity is impossible to monitor with site surveys and chart review alone.
Twice-weekly visits for 4 weeks, then weekly for 4 weeks. Patients who drop out before week 8 never see Spravato's real benefit. Predicting and intervening on drop-off risk is a multi-billion-dollar problem hiding in plain sight.
Bretisilocin, COMP360, and long-acting ketamines are all coming. Spravato's payer story needs to evolve from "first approved" to "best real-world outcomes," continuously, across the certified-site network.
J&J's schizophrenia, bipolar, and MDD portfolio overlaps in patient identification, switching, and discontinuation behaviors. A unified behavioral-evidence layer across Spravato and Caplyta unlocks brand-level intelligence the industry doesn't have today.
Our platform pairs in-clinic AI hardware with multimodal behavioral analytics and a custom algorithm engine, already proven in TDScreen and Check on Mom. Here's how each maps to Spravato's next phase.
A clinical-grade camera and directional audio rig that drops into any Spravato-certified site in minutes. It verifies REMS-required observation periods, vital sign timing, and patient interactions with the same fidelity at every site. Videra's AI flags protocol deviations in real time, before they become FDA findings.
Our ASSESS platform analyzes voice, video, and language at every visit and between visits. What ECHO did with 570 patients in two years, we run continuously across the certified-site network: durable response signals, functional outcomes, and discontinuation predictors all surfaced in real time.
We don't stop at data collection. We build condition-specific algorithms on real patient data, with peer-reviewed results. For Spravato, that means proprietary models that flag induction drop-off risk early, identify which patients will sustain response, and turn 7,000 certified sites into a learning network.
AI-powered tardive dyskinesia screening built on the AIMS standard. AUC 0.89 vs. trained raters, peer-reviewed in J Clin Psychiatry.
Conversational AI + video screener for postpartum depression. Used in real homes, on real devices, validated against clinical frameworks.
Multimodal AI model trained across the certified-site network, combining vocal, facial, and engagement biomarkers to predict induction drop-off risk and identify durable responders weeks ahead of MADRS.
Your priorities for Spravato and the broader Janssen psych portfolio, mapped to capabilities Videra already has in production.
Videra's network isn't our customer base. It's the living dataset that powers every algorithm we build. For AbbVie, that means real clinical depth and peer-reviewed validation.
We'd welcome a 30-minute session to walk AbbVie's Neuroscience team through a tailored, protocol-by-protocol proposal for bretisilocin and the broader psychiatry pipeline.